High cortisol levels are associated with cognitive impairment no-dementia (CIND) and dementia

Clinica Chimica Acta

Volumn 423, Issue , 2013, Pages 18-22

  Lara, Vivian P ^a   Caramelli, Paulo ^a   Teixeira, Antônio L ^a   Barbosa, Maira T ^a   Carmona, Karoline C ^a   Carvalho, Maria G ^a   Fernandes, Ana P ^a   Gomes, Karina B ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

APOE; Cognitive impairment no dementia; Cortisol; Dementia

Indexed keywords

APOLIPOPROTEIN E; HYDROCORTISONE;

AGED; ARTICLE; BODY MASS; CHEMOLUMINESCENCE; CIRCADIAN RHYTHM; COGNITIVE DEFECT; COGNITIVE IMPAIRMENT NO DEMENTIA; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; APOLIPOPROTEINS E; COGNITION DISORDERS; DEMENTIA; FEMALE; GENOTYPE; HUMANS; HYDROCORTISONE; MALE;

EID: 84877817192     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.04.013     Document Type: Article

References (41)

1. World Health Organization Global brief for World Health Day 2012 (online) [Available at:], [Accessed November 2, 2012]. http://www.who.int/world-health-day/2012/en/index.html.
2. Caramelli P., Barbosa M.T., Sakurai E., et al. Pietà Study Group, the Pietà study: epidemiological investigation on successful brain aging in Caeté (MG), Brazil, methods and baseline cohort characteristics. Arq Neuropsiquiatr 2011, 69:579-584.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington DC. 4th ed.
4. Fratiglioni L., De Ronchi D., Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999, 15:365-375.
5. Sereniki A., Vital M.A.B.F. A doença de Alzheimer: aspectos fisiopatológicos e farmacológicos. Rev Psiquiatr Rio Gd Sul 2008, 30:1-17.
6. Cacabelos R. Pharmacogenomics in Alzheimer's disease. Methods Mol Biol 2008, 448:213-357.
7. Neto J.G., Tamelini M.G., Forlenza O.V. Diagnóstico diferencial das demências. Rev Psiq Clín 2005, 32:119-130.
8. Cacabelos R. Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat 2007, 3:303-333.
9. Ojopi E.P.B., Bertoncini A.B., Dias Neto E. Apolipoproteína E e a doença de Alzheimer. Rev Psiq Clín 2004, 31:26-33.
10. Bahia V.S., Kok F., Marie S.N., Shinjo S.O., Caramelli P., Nitrini R. Polymorphisms of APOE and LRP genes in Brazilian individuals with Alzheimer disease. Alzheimer Dis Assoc Disord 2008, 22:61-65.
11. Bekris L.M., Yu C.-E., Bird T.D., Tsuang D.W. Genetics of AD. J Geriatr Psychiatry Neurol 2010, 23:213-227.
12. Ebly E.M., Hogan D.B., Parhad I.M. Cognitive impairment in the nondemented elderly, results from the Canadian Study of Health and Aging. Arch Neurol 1995, 52:612-619.
13. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256:183-194.
14. Marengoni A., Fratiglioni L., Bandinelli S., Ferrucci L. Socioeconomic status during lifetime and cognitive impairment no-dementia in late life: the population-based aging in the Chianti Area (InCHIANTI) Study. J Alzheimers Dis 2011, 24:559-568.
15. Low L.F., Brodaty H., Edwards R., et al. The prevalence of "cognitive impairment no dementia" in community-dwelling elderly: a pilot study. Aust N Z J Psychiatry 2004, 38:725-731.
16. Gauthier S., Reisberg B., Zaudig M., et al. International Psychogeriatric Association, Expert Conference on mild cognitive impairment, mild cognitive impairment. Lancet 2006, 367:1262-1270.
17. Graham J.E., Rockwood K., Beattie B.L., et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997, 349:1793-1796.
18. Di Carlo A., Lamassa M., Baldereschi M., et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology 2007, 68:1909-1916.
19. McEwen B.S., Seeman T. Protective and damaging effects of mediators of stress. Elaborating and testing the concepts of allostasis and allostatic load. Ann N Y Acad Sci 1999, 896:30-47.
20. Fries E., Dettenborn L., Kirschbaum C. The cortisol awakening response (CAR): facts and future directions. Int J Psychophysiol 2009, 72:67-73.
21. Lupien S.J., Maheu F., Tu M., Fiocco A., Schramek T.E. The effects of stress and stress hormones on human cognition: implications for the field of brain and cognition. Brain Cogn 2007, 65:209-237.
22. Jacobson L., Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 1991, 12:118-134.
23. Brindley D.N., Rolland Y. Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis. Clin Sci (Lond) 1989, 77:453-461.
24. Gil-Bea F.J., Aisa B., Solomon A., et al. HPA axis dysregulation associated to apolipoproteína E4 genotype in Alzheimer's disease. J Alzheimers Dis 2010, 22:829-838.
25. Kuningas M., de Rijk R.H., Westendorp R.G., Jolles J., Slagboom P.E., van Heemst D. Mental performance in old age dependent on cortisol and genetic variance in the mineralocorticoid and glucocorticoid receptors. Neuropsychopharmacology 2007, 32:1295-1301.
26. Lupien S.J., de Leon M., de Santi S., et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1998, 1:69-73.
27. Csernansky J.G., Dong H., Fagan A.M., et al. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry 2006, 163:2164-2169.
28. Schrijvers E.M., Direk N., Koudstaal P.J., et al. Associations of serum cortisol with cognitive function and dementia: the Rotterdam Study. J Alzheimers Dis 2011, 25:617-671.
29. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1987, American Psychiatric Association, Washington, DC. 3rd ed.
30. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990, 31:545-548.
31. Azad N.A., Al Bugami M., Loy-English I. Gender differences in dementia risk factors. Gend Med 2007, 4:120-129.
32. Launer L.J., Andersen K., Dewey M.E., et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses, EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999, 52:78-84.
33. Kalaria R.N., Maestre G.E., Arizaga R., et al. World Federation of Neurology Dementia Research Group, Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008, 7:812-826.
34. Prince M. Epidemiology of dementia. Psychiatry 2007, 6:488-490.
35. Nitrini R., Bottino C.M., Albala C., et al. Prevalence of dementia in Latin America: a collaborative study of population-based cohorts. Int Psychogeriatr 2009, 21:622-630.
36. Atti A.R., Palmer K., Volpato S., Winblad B., De Ronchi D., Fratiglioni L. Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc 2008, 56:111-116.
37. Beluche I., Carrière I., Ritchie K., Ancelin M.L. A prospective study of diurnal cortisol and cognitive function in community-dwelling elderly people. Psychol Med 2010, 40:1039-1049.
38. Lind K., Edman A., Nordlund A., Olsson T., Wallin A. Increased saliva cortisol awakening response in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007, 24:389-395.
39. Arsenault-Lapierre G., Chertkow H., Lupien S. Seasonal effects on cortisol secretion in normal aging, mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2010, 31:1051-1054.
40. Peskind E.R., Wilkinson C.W., Petrie E.C., Schellenberg G.D., Raskind M.A. Increased CSF cortisol in AD is a function of APOE genotype. Neurology 2001, 56:1094-1098.
41. Agosta F., Vossel K.A., Miller B.L., et al. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci USA 2009, 106:2018-2022.